---
input_text: 'What has been the impact of new drug treatments on epilepsy? PURPOSE
  OF REVIEW: Nearly two dozen antiseizure medications (ASMs) with different mechanisms
  of action have been introduced over the past three decades with the aim of providing
  better efficacy or safety profile than the previous drugs. Several new ASMs with
  improvement on a classic drug family or have novel mechanisms of action have been
  recently approved for epilepsy. The present review explored recent studies or guidelines
  on new agents and discussed the potential impact of these novel treatments on epilepsy
  management and future directions of research. RECENT FINDINGS: Long-term cohort
  studies showed that, collectively, the second-generation did not improve the overall
  prognosis of epilepsy. Individual monotherapy studies showed similar efficacy of
  second-generation (levetiracetam and zonisamide) and third-generation (eslicarbazepine
  acetate and lacosamide) ASMs compared to controlled-release carbamazepine for the
  treatment of focal epilepsy. However, there appears to be no evidence to support
  any second-generation or third-generation ASMs to be as efficacious as valproate
  monotherapy for generalized and unclassified epilepsies. Cannabidiol adjunctive
  treatments were found to be efficacious for Dravet syndrome and Lennox-Gastaut syndrome.
  Although most newer generation ASMs are less prone to drug-drug interactions, stiripentol
  and cannabidiol can elevate the plasma concentration of N-desmethylclobazam, the
  active metabolite of clobazam. Generally speaking, the second-generation ASMs have
  lower teratogenic risk than the older drugs but there is scant study on neurodevelopmental
  effect of third-generation ASMs. SUMMARY: Although the newer generation ASMs may
  not have improved the overall seizure control they have advantages in terms of drug-drug
  interactions and teratogenicity, and thus offer valuable individualized options
  in the treatment of epilepsy.'
raw_completion_output: |-
  primary_disease: Epilepsy

  medical_actions: Antiseizure medications (ASMs); Individual monotherapy; Cannabidiol adjunctive treatments

  symptoms: Seizures

  chemicals: Levetiracetam; Zonisamide; Eslicarbazepine acetate; Lacosamide; Controlled-release carbamazepine; Valproate; Cannabidiol; Stiripentol; N-desmethylclobazam; Clobazam

  action_annotation_relationships: Antiseizure medications (ASMs) TREATS seizures IN Epilepsy; Individual monotherapy (with levetiracetam) TREATS focal epilepsy IN Epilepsy; Individual monotherapy (with zonisamide) TREATS focal epilepsy IN Epilepsy; Individual monotherapy (with eslicarbazepine acetate) TREATS focal epilepsy IN Epilepsy; Individual monotherapy (with lacosamide) TREATS focal epilepsy IN Epilepsy; Cannabidiol adjunctive treatments TREATS Dravet syndrome IN Epilepsy; Cannabidiol adjunctive treatments TREATS Lennox-Gastaut syndrome IN Epilepsy
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Cannabidiol adjunctive treatments TREATS Lennox-Gastaut syndrome IN Epilepsy

  ===

extracted_object:
  primary_disease: MONDO:0005027
  medical_actions:
    - Antiseizure medications (ASMs)
    - Individual monotherapy
    - Cannabidiol adjunctive treatments
  symptoms:
    - HP:0001250
  chemicals:
    - CHEBI:6437
    - CHEBI:10127
    - CHEBI:87016
    - CHEBI:135939
    - Controlled-release carbamazepine
    - CHEBI:60654
    - CHEBI:69478
    - CHEBI:228488
    - CHEBI:190616
    - CHEBI:31413
  action_annotation_relationships:
    - subject: Antiseizure medications
      predicate: TREATS
      object: HP:0001250
      qualifier: MONDO:0005027
      subject_extension: Antiseizure medications
    - subject: Individual monotherapy
      predicate: TREATS
      object: focal epilepsy
      qualifier: MONDO:0005027
      subject_qualifier: with levetiracetam
      subject_extension: CHEBI:6437
    - subject: Individual monotherapy
      predicate: TREATS
      object: HP:0001250
      qualifier: MONDO:0005027
      subject_qualifier: with zonisamide
      subject_extension: CHEBI:10127
      object_extension: focal
    - subject: Individual monotherapy
      predicate: TREATS
      object: focal epilepsy
      qualifier: MONDO:0005027
      subject_qualifier: with eslicarbazepine acetate
      subject_extension: CHEBI:87016
    - subject: Individual monotherapy
      predicate: TREATS
      object: focal epilepsy
      qualifier: MONDO:0005027
      subject_qualifier: with lacosamide
      subject_extension: CHEBI:135939
    - subject: adjunctive treatments
      predicate: TREATS
      object: Dravet syndrome
      qualifier: MONDO:0005027
      subject_extension: CHEBI:69478
    - subject: adjunctive treatments
      predicate: TREATS
      object: Lennox-Gastaut syndrome
      qualifier: MONDO:0005027
      subject_extension: CHEBI:69478
named_entities:
  - id: MONDO:0100135
    label: Dravet syndrome
  - id: MAXO:0001187
    label: hysteroscopy
  - id: CHEBI:44915
    label: propofol
  - id: CHEBI:119915
    label: fentanyl
  - id: CHEBI:9130
    label: sevoflurane
  - id: HP:0001250
    label: seizures
  - id: CHEBI:6443
    label: Mirena
  - id: MONDO:0002602
    label: Central nervous system diseases
  - id: HP:0002011
    label: central nervous system diseases
  - id: MONDO:0005027
    label: Epilepsy
  - id: HP:0002014
    label: Diarrhea
  - id: HP:0000988
    label: Rash
  - id: CHEBI:228488
    label: Stiripentol
  - id: CHEBI:60654
    label: Valproate
  - id: CHEBI:69478
    label: Cannabidiol
  - id: CHEBI:80634
    label: 2-propyl-4-pentenoic acid (4-ene-VPA)
  - id: HP:0002373
    label: Febrile seizures
  - id: MAXO:0001298
    label: therapy
  - id: CHEBI:31413
    label: clobazam (CLB)
  - id: HP:0010819
    label: drop seizures
  - id: HP:0002329
    label: somnolence
  - id: HP:0004396
    label: decreased appetite
  - id: CHEBI:9925
    label: sodium valproate
  - id: MONDO:0016532
    label: Lennox-Gastaut syndrome
  - id: HP:0000729
    label: Autistic behaviors
  - id: HP:0033258
    label: Sudden unexpected death in epilepsy
  - id: MAXO:0001001
    label: Gene therapy
  - id: MONDO:0002125
    label: Status epilepticus
  - id: HP:0032656
    label: Febrile status epilepticus
  - id: MAXO:0001017
    label: vaccination
  - id: HP:0002069
    label: Generalized tonic-clonic seizure
  - id: CHEBI:3359
    label: CBDA
  - id: CHEBI:167557
    label: CBCA
  - id: CHEBI:66964
    label: Delta9-tetrahydrocannabinol (THC)
  - id: CHEBI:39867
    label: Valproic acid
  - id: CHEBI:5000
    label: Fenfluramine
  - id: HP:0033349
    label: recurrent seizures
  - id: MAXO:0000058
    label: Drug treatment
  - id: HP:0020219
    label: motor seizures
  - id: CHEBI:76720
    label: Antisense oligonucleotides
  - id: MAXO:0001593
    label: ASO therapy
  - id: HP:0012378
    label: Fatigue
  - id: HP:0001945
    label: Pyrexia
  - id: HP:0001654
    label: valvular heart disease
  - id: HP:0002092
    label: pulmonary arterial hypertension
  - id: HP:0002133
    label: Status epilepticus
  - id: CHEBI:17115
    label: vaccine(s)
  - id: MONDO:0100062
    label: Developmental and/or epileptic encephalopathies (DEE)
  - id: HP:0001260
    label: dysarthria
  - id: HP:0001254
    label: lethargy
  - id: HP:0002315
    label: headache
  - id: CHEBI:233158
    label: soticlestat
  - id: CHEBI:34310
    label: 24S-hydroxycholesterol (24HC)
  - id: CHEBI:9586
    label: Tiagabine
  - id: CHEBI:6437
    label: Levetiracetam
  - id: HP:0000708
    label: behavioral problems
  - id: CHEBI:16113
    label: Cholesterol
  - id: MAXO:0001394
    label: Oral administration
  - id: CHEBI:173124
    label: 2-linoleoyl glycerol (2-LG)
  - id: CHEBI:52392
    label: 2-AG
  - id: CHEBI:2700
    label: anandamide
  - id: CHEBI:52640
    label: N-acylethanolamines
  - id: CHEBI:35623
    label: Anticonvulsants
  - id: MAXO:0000942
    label: Vagus nerve stimulation (VNS)
  - id: HP:0002360
    label: Sleep disturbance
  - id: HP:0001249
    label: Intellectual disability
  - id: HP:0001251
    label: ataxia
  - id: CHEBI:42638
    label: fenfluramine (FFA)
  - id: HP:0032794
    label: Myoclonic seizures
  - id: CHEBI:190616
    label: N-desmethylclobazam
  - id: MONDO:0013801
    label: SCN8A encephalopathy
  - id: HP:0001263
    label: Developmental delay
  - id: HP:0100543
    label: Cognitive impairment
  - id: CHEBI:35493
    label: antipyretics
  - id: MAXO:0000932
    label: Electroencephalography (EEG)
  - id: HP:0002353
    label: EEG abnormalities
  - id: CHEBI:73601
    label: <Ketogenic diet (KD)>
  - id: CHEBI:49575
    label: diazepam
  - id: CHEBI:6931
    label: midazolam
  - id: CHEBI:3756
    label: clonazepam
  - id: CHEBI:22720
    label: Benzodiazepines
  - id: MONDO:0010083
    label: Succinic semialdehyde dehydrogenase deficiency
  - id: HP:0000739
    label: Anxiety
  - id: CHEBI:10127
    label: Zonisamide
  - id: CHEBI:87016
    label: Eslicarbazepine acetate
  - id: CHEBI:135939
    label: Lacosamide
